Cargando…
Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?
Autor principal: | Park, Jihye |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association for the Study of Intestinal Diseases
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831776/ https://www.ncbi.nlm.nih.gov/pubmed/35135074 http://dx.doi.org/10.5217/ir.2021.00170 |
Ejemplares similares
-
Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021) -
How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries?
por: Park, Jihye
Publicado: (2023) -
Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
por: Poylin, Vitaliy Y., et al.
Publicado: (2022) -
Choosing a Second Biologic Agent for Inflammatory Bowel Disease Patients—Cost Considerations and Clinical Outcomes
por: Clarke, Kofi
Publicado: (2020) -
Oral Health in Patients with Inflammatory Bowel Diseases Qualified for Biologic Treatment
por: Nijakowski, Kacper
Publicado: (2022)